Trials / Approved For Marketing
Approved For MarketingNCT05162443
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adagrasib (MRTX849) | adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen |
Timeline
- First posted
- 2021-12-17
- Last updated
- 2025-08-26
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05162443. Inclusion in this directory is not an endorsement.